Hidradenitis Suppurativa News

Patients treated with bimekizumab for moderate to severe hidradenitis suppurativa exhibited rapid and clinically meaningful responses that were maintained up to 48 weeks, according to new data published in The Lancet.

Simlandi injection, an interchangeable biosimilar to Humira, is now available in the U.S. for the treatment of psoriatic arthritis, plaque psoriasis and other conditions, Teva Pharmaceuticals and Alvotech announced in a press release.

The FDA has approved a citrate-free, high-concentration formulation of the interchangeable adalimumab biosimilar Cyltezo to treat multiple chronic inflammatory diseases, according to the manufacturer.

Healio has compiled April’s most-read news in dermatology.

The European Commission has granted marketing authorization for Bimzelx to treat adults with active moderate to severe hidradenitis suppurativa, according to a UCB press release.

UCB has announced the launch of Make HStory, an educational campaign that provides resources on hidradenitis suppurativa to dermatologists as well as patients living with the disease, according to a press release.

Healio has compiled March’s most-read news in dermatology.

SAN DIEGO — In this Healio video perspective from the American Academy of Dermatology Annual Meeting, Hadar Lev-Tov, MD, shares topline results from an extra analysis of the BE HEARD I and II studies.

Supplemental biologics license applications for Bimzelx for the treatment of hidradenitis suppurativa and a 2 mL autoinjector device for the drug have been accepted by the FDA, UCB announced in a press release.

Incyte has entered into a collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib, the companies announced in a press release.